Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,401–1,500 of 1,733
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Lavrentaki, A., & Ntali, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_172-1
Casals, G., Ferrer, R., Urgell, E., Escobar-Morreale, H. F., Argente, J., Sesmilo, G., & Biagetti, B. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2022-0121 · Cited by 1
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Chapter 32: Venous Thromboembolic Disease
Trujillo, T. C. (2026) · doi:10.21019/9781582123875.ch32
Gender-Affirming Hormonal Treatment in Transgender People Assigned Female at Birth (AFAB)
Castella, L., Ledda, F., Bichiri, A., Muzio, J., & Motta, G. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_56-1
Co-occurring Medical Disorders
Meyer, A., & Rajagopal, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-33404-8_21
(2000) · Time to knit · doi:10.1016/s1879-8551(20)87246-7
Johnson, H. H., Clift, A. K., Huang, D. R., Foster, J., & El-Osta, A. A. R. (2025) · Research Square · doi:10.21203/rs.3.rs-6246872/v1
37-Year-Old Man With Fatigue and Erectile Dysfunction
Sytsma, T. T., & McCoy, R. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.028
Trattare o non trattare con testosterone l’ipogonadismo funzionale?
D’Andrea, S., & Dalmazio, G. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01692-z
“Per questo le diverse società scientifiche, nazionali e interna-zionali [1–3], raccomandano sempre le modifiche dello stile di vita e la correzione delle comorbidità sottostanti come primo approccio all’ipogonadismo funzionale età correlato.”
InfluentialCorsini, C., Pozzi, E., Belladelli, F., Bertini, A., Negri, F., Raffo, M., Boeri, L., Ventimiglia, E., Candela, L., d’Arma, A., et al. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01029-2 · Cited by 3
Regmi, A., Sami, A., Baral, S., Jain, V. K., & Iyengar, K. P. (2026) · The Knee · doi:10.1016/j.knee.2026.104637
Esteroides anabolizantes androgênicos: mecanismos de ação e possíveis efeitos colaterais
Loschi, R., & Ide, B. N. (2018) · Revista Brasileira de Nutrição Funcional · doi:10.32809/2176-4522.41.76.2
Особливості лікування цукрового діабету 2-го типу у людей похилого віку
Zein, W. A., & Mokhort, T. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.6.2019.185412
The influence of monoclonal antibodies for cancer treatment on the endocrine system
Dyrka, K., Witasik, D., Czarnywojtek, A., & Łącka, K. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.8889 · Cited by 1
Antonič, K. G. (2020) · Slovenian Medical Journal · doi:10.6016/zdravvestn.2921
Smolensky, M. H., Hermida, R. C., Sackett-Lundeen, L. L., Hermida‐Ayala, R. G., & Geng, Y. (2022) · Comprehensive physiology · doi:10.1002/cphy.c220014
Hubbard, L. C., Rajfer, J., & Rambhatla, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00115-1
Crill, C. M., & Fly, J. H. (2026) · doi:10.21019/9781582123875.ch33
Testosterontherapie: orale Androgene
Kalinchenko, S. Y., Tyuzikov, I. A., Mskhalaya, G. J., & Tishova, Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_13
Role of sex steroid hormone on hand grip strength and cognitive function in the elderly
Parwanto, E., Tjahyadi, D., Amalia, H., Hairunisa, N., Edy, H. J., Oladimeji, A. V., & Djebli, N. (2023) · Universa Medicina · doi:10.18051/univmed.2023.v42.329-345
“(84) (85-87) The results of this study are in line with the results of other studies which have demonstrated that sex hormone deficiency in the synthesis or action of sex hormones on target cells affects organ function.”
ResultSherman, J. (2026) · doi:10.21019/9781582123875.ch41
Diagnostic Uncertainty in a Patient With Late-Onset Hypogonadism-Like Symptoms: A Case Report
Ichino, K., Ide, H., Okui, N., & Horie, S. (2026) · Cureus · doi:10.7759/cureus.103830
“Testosterone measurement occurred once at 16:00 and did not meet repeated blood tests emphasized in diagnostic frameworks, usually in the morning [5,10].”
InfluentialMitkov, M., & Nyagolova, P. (2019) · Journal of Metabolic Syndrome
Obesity associated hypogonadism—a growing concern in metabolic syndrome
Majumdar, S., Jacob, J. J., & Jude, E. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00054-2 · Cited by 1
Testosterone Measurement, Use and Misuse
Handelsman, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_17
Adnan, S., & Afzal, S. (2026) · Health Science Reports · doi:10.1002/hsr2.73305
“Symptoms such as fatigue, low mood, sleep disturbance, reduced vitality, and sexual concerns are nonspecific and cannot be attributed to hormonal ageing on the basis of self‐reported AMS scores alone [6, 7].”
Kaufman, J. (2022) · doi:10.1093/med/9780198870197.003.0483
Low serum testosterone concentrations predict incident frailty in men with HIV
Dias, J. P., Fitzgerald, K. C., Seaberg, E., Wolinsky, S., Lake, J. E., Koletar, S. L., Shardell, M. D., Basaria, S. S., & Brown, T. T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag252
Erkrankungen der männlichen Gonaden
Hoffmann, I., & Behre, H. M. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00007-7
Lisco, G., Bartolomeo, N., Ramunni, M. I., Tullio, A. D., Carbone, M. D., Guastamacchia, E., Triggiani, V., & Giagulli, V. A. (2021) · Research Square · doi:10.21203/rs.3.rs-716137/v1
Newman, M. S., Smeaton, J., Gillson, G., & Jaferi, A. (2026) · Frontiers in Reproductive Health · doi:10.3389/frph.2026.1804311
“The available evidence supports serum T testing as the primary method for monitoring transdermal TRT in clinical practice, in line with the recommendations of multiple medical societies (16, 21).”
InfluentialIpogonadismo maschile indotto da esercizio fisico
Emerenziani, G. P., Izzo, G., Greco, F., & Aversa, A. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00793-1
Elevated Total Testosterone Level in an Adult with Erectile Dysfunction
Pant, V., Pyakurel, D., Gautam, K., Pradhan, S., & Shrestha, A. (2019) · Nepalese Medical Journal · doi:10.3126/nmj.v2i2.25987
Testosterone replacement therapy in puberty
Bouvattier, C. M., & Young, J. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.05.005
Xiao, Y., Jiang, D., Wang, S., Fu, L., Ye, L., Zheng, E., Lv, Z., Mu, Y.-M., Gong, W., & Guo, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-05563-3 · Cited by 3
Nieschlag, E., & Behre, H. M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_36-1
Fux, E., Schmid, R., Singh, N., Fleischer, S., Bauland, F., Köppl, D., Gaudl, A., Geistanger, A., Ceglarek, U., Rauh, M., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1266 · Cited by 1
Sanyal, D., Patra, S., & Rothman, M. S. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_926_25
Rastrelli, G., Maggi, M., & Corona, G. (2022) · doi:10.1093/med/9780198870197.003.0387
Chapter 46: Substance Use Disorder
Hurst, E. B. (2026) · doi:10.21019/9781582123875.ch46
Endogenous androgens, physical and cognitive function in healthy midlife men: A systematic review
Keren, D., Hayek, R., Toledano, Y., Strauss, T., Springer, S., & Goshen, A. (2026) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2026.112257
Adeleye, J. O., Onasanya, A., Sonuga, O. O., Esan, A., & Adebiyi, A. A. (2025) · PubMed Central
Les recommandations pour la prise en charge du déficit en testostérone
Burte, C., Lejeune, H., Faix, A., Desvaux, P., Almont, T., Cuzin, B., & Huyghe, É. (2021) · Sexologies · doi:10.1016/j.sexol.2021.06.006 · Cited by 1
Manoranjani, M. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i4s.5125
Graziana, J.-P. (2024) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2024.03.007
The Role of Post-Radical Prostatectomy Testosterone Therapy in Erectile Function Recovery
Huynh, L. M., Gevorkyan, R., & Ahlering, T. E. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0005
“19 Within the context of these definitions, the effect of testosterone on EF is immutable, with rates of hypogonadism among men with ED reported to be up to 35%.”
Андрогенний дефіцит із точки зору ризику серцево-судинних захворювань у чоловіків із гіпотиреозом
Pasyechko, N. V., Наумова, У. О., Krytskyy, T., & Naumova, L. V. (2023) · Терапевтика · doi:10.31793/2709-7404.2022.3-4.35
Amenorrhea Induced by Hydrocephalus Due to Tuberculous Meningitis: A Rare Case Report and Literature
Adnyana, I. B. P., Ritonga, M. A., Rachmawati, A., Tjahjadi, D., Anwar, R., & Hartanto, A. I. (2026) · International Medical Case Reports Journal · doi:10.2147/imcrj.s562039
Castro, H. M., Furcada, J. M., Vito, E. L. D., Suarez, S. M., Knoblovits, P., & Costanzo, P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.08.009
Estrogens and Male Osteoporosis
Rochira, V., & Madeo, B. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-96376-1_6 · Cited by 1
The lupus damage index revision program: Results from the item generation and reduction phases
Kundakci, B., Barber, M. R. W., Clarke, A. E., Johnson, S. R., Mak, A., Brunner, H. I., İnanç, M., Ramsey‐Goldman, R., Ruiz‐Irastorza, G., Ginzler, E. M., et al. (2026) · Lupus Science & Medicine · doi:10.1136/lupus-2026-002282 · Cited by 1
Ntais, C., Vantarakis, A., & Chatziprodromidou, I. P. (2026) · Medical Sciences · doi:10.3390/medsci14030418 · Cited by 1
“Clinical guidelines therefore emphasize that testosterone replacement therapy (TRT) should be reserved for men with consistent symptoms and unequivocally low testosterone concentrations, after exclusion of reversible causes and contraindications [8].”
Broul, M., Hujová, A., Liegertová, M., Langmaierová, K., & Albrecht, J. (2026) · Journal of Sex & Marital Therapy · doi:10.1080/0092623x.2026.2726480
Sexual Health and Hypertension
Camafort, M., Hanzu, F. A., & Poch, E. (2024) · Trends in andrology and sexual medicine · doi:10.1007/978-3-031-55080-5_21
Hormone replacement therapy, male
Wang, C., & Swerdloff, R. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00263-6
Self-citationEffect of Testosterone on Asthma Exacerbations
Nayak, Y. R., Deol, E., Doherty, J. M., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.013
Medication Use and Sexual Activity in Older Adults
Pizzol, D., Ilie, P. C., & Veronese, N. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-21029-7_9 · Cited by 2
Fritz, A. A., & Reinert, J. P. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241278786 · Cited by 1
“…OR androderm Transdermal gel 6,8 Once daily Secondary exposure to others More predictable absorption compared with the patch Transdermal solution 6,8 Once daily Secondary exposure to others More predictable absorption compared with the patch Transdermal patch 6 Once daily Secondary exposure to…”
Chapter 9: Biostatistics and Clinical Trial Design
Rowe, A. S. (2026) · doi:10.21019/9781582123875.ch9
HYPOGONADISM AND OBESITY: CORRELATION AND CLINICAL MANAGEMENT
Billarrubia, M., de Souza, L. B. S., Lima, C. V. P., Spósito, T. S. L., Souza, I. B., Matsuda, M. H., Pacagnan, H. F., Cunali, A. B., & Val, L. E. F. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592582229094
Yang, P., Niu, Z., Guo, J., Huang, T., Chang, D., & 黄晓朋 (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1903508
“In clinical practice, the diagnosis of male hypogonadism cannot rely on a single isolated biochemical measurement; it requires corroborating symptoms, signs, and reliable repeat testing (16–18).”
Potential of Andrology in Providing Male Health Services from Womb to Tomb: PESTEL Analysis
Jha, S. (2023) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1634
An Endogenous Proton-Powered Adaptive Nanomotor for Treating Muscle Atrophy
Liu, M. R., Liu, Z., Qiao, X., Chen, C., Guo, H., Gu, H., Li, J., & Sun, T. (2025) · Materials · doi:10.3390/ma18061351
Amalraj, A., Reshna, K. R., C., K. V. A., Jogy, A. M., Balakrishnan, P., & Gopi, S. (2026) · RSC Advances · doi:10.1039/d6ra02748b · Cited by 1
“86,87 In contrast, nutraceutical-based testosterone-support formulations such as Testoli are designed to stimulate endogenous testosterone biosynthesis rather than replace the hormone exogenously.”
Testosterone Effects on the Prostate: Focusing on Benign Prostatic Hyperplasia
Grutman, A. J., Su, Z. T., & Herati, A. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_31 · Cited by 1
Huang, R., Huang, M., & Zhang, R. (2026) · HORMONES · doi:10.1007/s42000-026-00833-9
Trans*Männer und die Testosterontherapie
Hohl, A., Lee, S. V. D. S., & Ronsoni, M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_21
Kocaman, B. B., Boyraz, N., Soltanova, L., Muradov, İ., Taze, S. S., Tunc, A., Çapar, M. U., Durcan, E., Turan, Ş., Şahin, S., et al. (2026) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdag066
Arreola-Ramírez, D. A., Anceno, A., Varela-Gómez, F. F., Guzmán-Martínez, N. B., Haddad-Servín, A., Muñoz-López, Y., Silva-Mendoza, C. A., Alvarado-Bahena, P. A., Cervantes-Zorrilla, R., Chávez-Fraga, J. H., et al. (2025) · Urology Case Reports · doi:10.1016/j.eucr.2025.103251
“6,10,11 12 – 14 This mirrors reports of paratesticular masses leading to endocrine failure via mass effect, with severity tied to tumor duration and size (3 cm here).”
Kaltsas, A., Gkioxaris, V., Giannakas, T., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187313
“Avoid testosterone monotherapy whenever fertility is desired [15–17] [G].”
InfluentialChapter 15: Acute Coronary Syndrome
Chilbert, M. R., & Rogers, K. C. (2026) · doi:10.21019/9781582123875.ch15
Chapter 42: Nonprescription Therapies
Melton, T. C. (2026) · doi:10.21019/9781582123875.ch42
Debunking Internet Myths: What Is the Best Approach?
Eschler, D. C., & Leffert, J. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-22720-3_5
Testicular Vasculitis Associated with Treatment with Sex Hormones
Nistal, M., & González‐Peramato, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-57847-2_5
Castro, H. M., Furcada, J. M., Vito, E. L. D., Suarez, S. M., Knoblovits, P., & Costanzo, P. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.08.016 · Cited by 1
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
Aboukhshaba, A., Almajed, E. H., Shunayf, M. B., Albawardy, M., AlThunayyan, A., Alsuwailim, A. M., Alhumaid, T., & Alhathal, N. K. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.250255 · Cited by 1
Chapter 25: Gastrointestinal Diseases
Russell, L. M. (2026) · doi:10.21019/9781582123875.ch25
Denham, H. R., & Hintz, M. M. (2026) · doi:10.21019/9781582123875.ch28
Hyperhidrose: wanneer doet overmatig zweten hormonaal lijden vermoeden?
Smet, S. D., Vanwonterghem, Y., Ongenae, K., Lapauw, B., & T'Sjoen, G. G. (2020) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.76.20.115
Hormone Deficiency Syndromes of the Hypothalamic-Pituitary Axis
Polu, S., Sarmiento-Ramon, J. C., Haque, N., & Karam, S. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-62187-2_11
Kelly, D. M., Nettleship, J. E., Gillett, M. M., & Jones, T. H. (2026) · Cells · doi:10.3390/cells15181633
“Clinically, this reinforces the need for careful patient selection, appropriate dose titration and regular biochemical monitoring to avoid sustained supraphysiological testosterone exposure [54,55].”
Lawand, J. J., Crutchfield, C. R., Holle, A. M., Sogbein, O. A., Khawaja, S. R., Ghilzai, U. M., Hill, B. W., Khan, A. Z., Horneff, J. G., & Abboud, J. A. (2026) · Shoulder & Elbow · doi:10.1177/17585732261437972
Preclinical Investigation into the Anti-hypogonadism Effects of Panax ginseng Root
Sharma, S., Kumar, J., Lakhanpal, A., & Ritu (2025) · Current Bioactive Compounds · doi:10.2174/0115734072374645250531084028
Rastrelli, G., Maggi, M., & Corona, G. (2025) · Springer eBooks · doi:10.1007/978-3-031-55405-6_56 · Cited by 2
Testosterone replacement therapy in older men: skeletal outcomes and fracture risk
Szarpak, L., Al-Jeabory, M., Pecold, J., & Maslyk, M. M. (2026) · The Aging Male · doi:10.1080/13685538.2026.2655544 · Cited by 1
Maggi, R. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737011347.793583823
Suspected hypogonadism and the importance of confirming the diagnosis - a case report
Marian, S., & McIntyre, P. (2023) · European Journal of Medical Case Reports · doi:10.24911/ejmcr/173-1678738418
“The Endocrine Society guidelines suggest using the lower limit of normal total testosterone (TT) that has been calibrated to the Centers for Disease Control and Prevention (CDC) standard, which is 264 ng/dl and can be used for CDC-certified assays [3].”
MethodLate-Onset Hypogonadism: Pathophysiology and Diagnosis
Rastrelli, G. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_27
The unbearable versatility of endocrine aging
Михеев, Р. К., Grigoryan, O. R., Волеводз, Н. Н., Rozhivanov, R. V., Sheremetyeva, E. V., Andreeva, E. N., & Mel'nichenko, G. A. (2026) · Problems of Endocrinology · doi:10.14341/probl13774 · Cited by 1
Pereira, L. C. D. L. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n8-029
Monitoring Haematocrit in Paediatric Patients Receiving Testosterone Therapy in Arab Countries
Alsaffar, H., Habeb, A. M., Hamza, R. T., & Deeb, A. (2021) · Cureus · doi:10.7759/cureus.17618
“detected by elevated haematocrit [7-9], the Endocrine Society recommends monitoring testosterone and haematocrit levels in men, three to six months after initiating the treatment, at 12 months and then annually [10], whilst the Endocrine Society of Australia recommends haematology profile three months after starting T…”
BackgroundEvaluación, indicaciones y contraindicaciones del tratamiento con testosterona en varones
Ortiz-Flores, A. E., Corrales, E. P., Castro, M. A., & Escobar-Morreale, H. F. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.10.008
Neuhof, C., & Hartmann, U. H. (2021) · Springer eBooks · doi:10.1007/978-3-662-62512-5_20
Alucozai, D., & Kwo, E. (2026) · Journal of Xenobiotics · doi:10.3390/jox16030106
“…a structured symptom inventory (menstrual regularity, libido, sexual function, mood, fatigue, weight trajectory, and vasomotor symptoms) together with a biochemical panel: morning (08:00–09:00) serum cortisol, estradiol, LH, FSH, prolactin, total testosterone, DHEAS, and TSH with free T4 [36,37].”
Testosterone Replacement Therapy
Amory, J. K., & Amory, T. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_18
The APhA Complete Review for Pharmacy, 14th Ed.
Franks, A. S., Parker, R. B., & Rogers, K. C. (2026) · doi:10.21019/9781582123875
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.